Consensus $4.48. Sees FY23 revenue $133.5B-$137.5B, consensus $134.8B. The company said, "Raising full-year sales guidance to $133.5 billion to $137.5 billion reflecting Summit Health acquisition, refreshed currency rates, and first quarter sales ahead of expectations. U.S. Healthcare targets raised with Summit Health announcement on November 7, 2022, including fiscal year 2025 sales goal to $14.5 billion to $16.0 billion, up from $11.0 billion to $12.0 billion previously, and positive adjusted EBITDA expected for the segment by the end of fiscal year 2023. Increased clarity into the Company’s long-term growth algorithm, building to low-teens adjusted EPS growth in fiscal year 2025 and beyond."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on WBA:
- Walgreens Boots Alliance Inc. Earnings Update: Did it Beat Estimate Forecasts?
- Walgreens Down Even as Q1 Results Beat Estimates
- Walgreens (NASDAQ:WBA) Pioneering Abortion Pill Sales
- Walgreens plans to sell abortion pill following FDA rule change, WSJ reports
- Notable companies reporting before tomorrow’s open
